142 results about "Programmed cell death" patented technology

The invention discloses application of an MCU (microprogrammed control unit) inhibitor in preparation of a medicine for preventing or treating intestinal ischemia-reperfusion injury, and relates to the technical field of biological medicine, and the MCU inhibitor comprises one or two of a reagent for inhibiting MCU gene expression and a reagent for inhibiting MCU protein activity. The MCU inhibitor disclosed by the invention is beneficial to relieving intestinal mucosa injury and inflammatory change of intestinal tissues, improving completeness of a villus structure, reducing pathological injury degree score of the intestinal tissues and relieving cell apoptosis degree in the intestinal tissues, so that the MCU inhibitor is beneficial to relieving programmed death of intestinal mucosa cells; as a main component, the pharmaceutical composition is beneficial for preventing or treating intestinal ischemia-reperfusion injury.

The invention relates to anti-drug neutralizing antibody analysis. In particular, the present application relates to methods for detecting neutralizing antibodies against a vascular endothelial growth factor (VEGF) binding moiety and a programmed cell death ligand-1 (PD-L1) binding moiety in a biological sample from an individual administered a bispecific antibody drug comprising the VEGF binding moiety.

The present invention provides a class of programmed cell death inhibitors, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, the compound being as shown in Formula I. The present invention also provides a method for preparing the compound and a pharmaceutical composition comprising the compound or a use thereof in treating or preventing diseases or conditions associated with programmed cell death and / or human receptor-interacting protein 1 kinase (RIPK1).

An anti-PD1 (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and / or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoclonal antibody can bind to PD1 specifically, relieve immunosuppression of PD1 on an organism specifically and activate T lymphocytes.

The invention provides a tumor exosome (TDEs) fluorescence detection method based on tandem hybrid chain reaction (HCR) and selective coordination, and aims to combine an aptamer, a tandem enzyme-free amplification technology and selective coordination of Cu < 2 + > to analyze a clinical lung cancer blood sample. The programmed cell death ligand 1 (PD-L1) biomarker overexpressed on the surface of the TDEs is selected as a target for detecting the exosome. The HCR can easily generate a large amount of double-stranded DNA, so that the HCR can be used as a means for signal amplification. The high affinity of the aptamer to the protein will affect the tandem HCR reaction and then modulate the HCR product. Cu < 2 + > and a double-stranded DNA product are utilized to form a compound, and a fluorescence signal of calcein can be accurately adjusted, so that accurate fluorescence quantification is performed on the concentration of TDEs.

The invention provides a lung adenocarcinoma prognostic marker and a model, constructs a lung adenocarcinoma prognostic model based on mRNA and lncRNA related to programmed cell death (PCD), and synthesizes bioinformatics analysis and experiments to explore the biological effect of the lncRNA model in lung adenocarcinoma. The prognosis model covers all PCD pathways and various molecules, has stable prognosis prediction accuracy, and can provide a potential molecular target for personalized treatment. According to the method disclosed by the invention, the PCD-related mRNA and lncRNA are integrated to construct a lung adenocarcinoma diagnosis model suitable for Chinese population, so that the identification capability of tumor patient classification is enhanced from multiple aspects, the accuracy and reliability of prognosis prediction are improved, powerful support can be provided for promoting personalized treatment strategies of lung adenocarcinoma patients, and the method is suitable for popularization and application.

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as V-domain immunoglobulin suppressor of T-cell activation (VISTA) inhibitors or as dual inhibitors of VISTA and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA and its ligands, PD-1, PD-L1, and / or PD-L2.

Disclosed are a method, a device, and an information processing program for determining, by using refractive index distribution data pertaining to an object to be observed, the region of a cell that has undergone programmed cell death in the object to be observed.

Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules or antigen-binding fragments thereof that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.

The invention relates to tilletia foetida, in particular to a tilletia foetida effect protein TlRlpA and application thereof. The invention provides a Tilletia foetida effect protein, and the amino acid sequence of the Tilletia foetida effect protein is shown as SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. The effector protein can effectively inhibit programmed death of plant cells induced by BAX, and plays an important role in inhibiting a plant defense reaction process. The invention lays a foundation for deeply researching the pathogenesis of the tilletia foetida, excavating the tilletia foetida-resistant gene of the wheat and developing the tilletia foetida-resistant wheat variety.

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

The present invention relates to a multispecific antibody targeting programmed cell death receptor-1 (PD-1) and a vascular endothelial growth factor (VEGF), a pharmaceutical composition comprising the multispecific antibody, a nucleic acid molecule and a vector encoding the multispecific antibody, a host cell, and use thereof for treating tumors.

This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

The present application provides antibodies including antigen binding fragment thereof that specifically recognizing programmed cell death 1 ligand 1 (PD-L1). Also provided are methods of making and using these antibodies.

Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. In certain embodiments, the one or more additional antigen comprises Programmed cell death ligand 1 (PDL1).

Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.

The invention discloses a targeted enhanced copper death-immunomodulator and a preparation method and application thereof, and belongs to the technical field of medical materials.The targeted enhanced copper death-immunomodulator comprises a polydopamine nanoparticle (PDA) substrate and a CuO2 nano-dot compounded CuO2 PDA nano-composite, the CuO2 PDA nano-composite is wrapped with a cell membrane, and the cell membrane is coated with a polydopamine nano-particle (PDA) substrate and a polydopamine nano-particle (PDA) nano-dot. According to the invention, a targeting ligand of a programmed cell death ligand-1 (Program Cell Death Ligand 1, PD-L1) is grafted on a cell membrane, and the targeting ligand of the Program Cell Death Ligand 1 (PD-L1) is grafted on the cell membrane. The regulator can be efficiently accumulated to a tumor site in a targeted manner, on one hand, the regulator can produce H2O2 in situ in a tumor, the intracellular oxidation-reduction balance is broken, the yield of active oxygen in the tumor is enhanced, and then tumor cell copper death is enhanced; on the other hand, the regulator can durably reduce the abundance of PD-L1 on the surfaces of tumor cells, and finally the purpose of multi-path combined efficient tumor immunotherapy is achieved.

The present invention relates to combination therapy compositions and methods of combination therapy for the treatment of cancer. The present invention discloses a composition comprising: (i) an effective amount of a programmed cell death protein-1 (PD-1) inhibitor capable of blocking a PD-1 pathway, partially recovering the function of T cells, and enabling these cells to continue killing tumor cells; and (ii) an effective amount of a glucosylceramide synthetase (GCS) inhibitor capable of enhancing the activity of the immune system; wherein the immunosuppressive agent is administered intravenously by using an intravenous dosage form, and the GCS inhibitor is administered orally by using an oral dosage form. The tumor growth can be effectively inhibited by using the composition and the combined treatment method disclosed by the invention.

The present disclosure generally relates to binding agents capable of targeting tumor cells and / or immune cells and their use to treat cancer. The binding agents of the present disclosure comprise one or more antigen-binding domains of a single-domain antibody capable of binding to cluster of differentiation 36 (CD36), programmed cell death protein 1 (PD-1), and / or cluster of differentiation 47 (CD47). The binding agents of the present disclosure may be monospecific or multispecific and may be in monomeric or multimeric form.

Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and Vascular endothelial growth factor receptor 2 (VEGFR2), related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

Provided is the use of a genetically engineered phage expressing a first peptide targeting a Programmed Cell Death protein 1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) and a second peptide targeting a cancer-related antigen for enhanced efficacy in cancer treatment. Thus, provided are methods for improved anti-cancer therapy, especially in the treatment of solid tumors, by using a recombinant phage that is capable of specifically targeting the PD-1 / PD-L1 pathway and specifically targeting a cancer antigen, as well as compositions and kits useful for such treatment methods.

To provide engineered PD-1 antibodies and uses thereof.SOLUTION: In some aspects, provided herein are antibodies that bind to PD-1. Antibodies provided herein, in some cases, agonize PD-1 signaling. Antibodies provided herein, in some cases, have modified Fc region. In other aspects, provided herein are compositions, methods of use, methods of making, and kits relating to antibodies that bind to PD-1. In some aspects, provided herein are methods of suppressing immune cells expressing programmed cell death 1 (PD-1), the methods comprising contacting the immune cells with an antibody that specifically binds to PD-1 and enhances an interaction between PD-1 and PD-L1 on a surface of the immune cells.SELECTED DRAWING: None

The disclosure provides amino acid sequence variants of programmed cell death protein 1 (PD-1) that can bind to either or both of its ligands, PDL-1 or PDL-2. The disclosure relates to ligand-binding fragments of the PD-1 variant sequences, conjugates, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., PD-1 variants and ligand-binding fragments thereof, in the treatment of checkpoint pathway-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, as well as diseases, disorders, and conditions associated with immune deficiency, immune insufficiency, and / or subjects who are immune compromised.

The invention provides an application of OGA as an inhibition target in preparation of drugs for treating GBC, and relates to the technical field of biomedicine.According to a specific verification test, it is found that GBC cells transfer OGA to neurons through EVs, so that glycosylation of RIPK1 is inhibited, phosphorylation and activation of RIPK1 are promoted, and finally neuronal necroptosis is induced. RIPK1 is a core factor for regulating and controlling cell survival, inflammatory response and programmed death, and is activated through a compound IIb pathway under the action of exogenous OGA. EV-induced invasion and necroptosis can be remarkably inhibited through neuron OGA knock-down, so that the aim of treating GBC is achieved.

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

The invention discloses a rice disease resistance defense regulation gene SRWD2 as well as an encoding protein and application thereof. According to the invention, a rice disease spot-like mutant tb18 is taken as an experimental material, a rice disease resistance defense regulation gene SRWD2 is separated through strategies such as MutMap positioning and transgene complementation, the nucleotide sequence of the gene is shown as SEQ ID NO.1, and the sequence of a protein coded by the gene is shown as SEQ ID NO.2. The biological function of the SRWD2 gene is analyzed, a theoretical basis is provided for clarification of a molecular mechanism of programmed cell death and defense reaction of plants, the gene mutation site is introduced into the plants through gene engineering or conventional means, the disease resistance can be remarkably enhanced, and the gene has important application value in the aspect of disease-resistant variety cultivation of the plants.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

The invention belongs to the technical field of bioelectricity medicine and cell therapy, and particularly relates to a system for carrying out intracellular electric treatment based on ultrahigh-frequency ultrashort pulses and application of the system. The system comprises a high-voltage ultrashort pulse generation module, a control module and an adherent cell processing module, wherein the high-voltage ultrashort pulse generation module is respectively connected with the control module and the adherent cell processing module; the control module presets a plurality of pulse parameter combinations, the high-voltage ultrashort pulse generation module outputs a pulse electric field with preset parameters according to an instruction sent by the control module, and the pulse electric field acts on an organelle through the adherent cell processing module. High-frequency ultrashort pulses are adopted, the unique electric field distribution characteristic of the high-frequency ultrashort pulses can penetrate through cell membranes without causing permanent damage, and the high-frequency ultrashort pulses directly act on specific organelles such as mitochondria, endoplasmic reticulum and lysosome. And the system can flexibly induce four main programmed cell death modes, is suitable for different treatment requirements, and is beneficial to precise medical treatment.